IHU Liryc Medical Operation

Bordeaux: IHU Liryc, a medical breakthrough for atrial fibrillation

Last updated:

Health is at the heart of the concerns, and the IHU Liryc is mobilizing to bring new solutions to the market. To overcome diseases that affect the heart rate, the Institute is multiplying experiments to develop revolutionary techniques. The latest, electroporation, offers great opportunities for medicine. A state-of-the-art solution, more efficient, faster, but above all more adapted to new needs.

IHU Liryc, a Bordeaux Institute involved in medical progress

The Institute of Rhythmology and Cardiac Modeling exists since 2012 in Bordeaux. It was founded as part of the Investments for the Future program initiated by the French State. The IHU Liryc intervenes as part of a public health mission. The Institute’s mission is to boost research and medical innovation in terms of electrical dysfunctions of the heart in France. An important mission to advance medicine and offer considerable progress for patients.

The latest research from IHU Liryc concerns electroporation. A therapy for the benefit of patients who suffer from cardiac fibrillation. Until now, ablation was done by catheter, using thermal energies to isolate pulmonary veins and exclude arrhythmia. However, there is no such thing as zero risk in medicine. But this operation, close to a vital organ such as the heart, brings risks of collateral damage or relapses.

The electroporative ablation proposed by the IHU Liryc would save more than 11 million people in Europe. 11 million people suffer from this pathology, without treating it. Less than 4% of patients with atrial fibrillation seek treatment. It is much more effective than catheter ablation, but also faster. Indeed, an intervention can be done in less than an hour, which limits the risks for the patient. The operation presents fewer risks, the technique being much more precise.

Operation medical patient surgery
Electroporation saves time and efficiency.

Become the reference energy in international recommendation

Faced with this success, the IHU Liryc sees the full potential of this operation technique, and has high hopes. That, first of all, to operate with electroporation more than 50% of people who suffer from atrial fibrillation. But also that of becoming the reference energy for the treatment of pathology on an international scale. In the past 30 years, no other technique has brought such a level of hope to medicine.

The Director General of IHU Liryc, Professor Pierre JAÏS, is supported by nine renowned European clinical centres. Together, they are working on the research program on this subject to show the importance of this breakthrough… And prove superiority in terms of result than catheter electroporation.

Hu Liryc also benefits from the support of the European Union as part of this project. The European Union has invested €6 million in line with the Horizon 2020 programme, which boosts research and development. This endowment allows IHU Liryc to create seven new jobs in Gironde, but also to invest in state-of-the-art equipment and tools. The Gironde capital still holds great promises for the medical future, and innovation…

Sources:

  1. Medical innovation, a top priority of IHU Liryc to overcome heart rhythm diseases. Press release of the IHU Liryc published in October 2021
  2. Care IHU Liryc
  3. Horizon 2020
Abonnez-vous à la Newsletter

X